Fig. 3.

Survival of mice immunized with the different vaccines in a prophylactic setting. DC were derived from bone marrow cells after 6 days of culture with GM-CSF and IL-4. On day 7, CD11c positive cells were matured 6 h with LPS and loaded with CP-peptides or TFA-peptides for the last 90 min of maturation. PBS (n = 11), unloaded mature DC (n = 23), CP-peptides alone (n = 8), TFA-peptides (n = 8), DC/CP (n = 8), or DC/TFA (n = 21) were administered intraperitoneously 20 and 10 days prior to tumor challenge. Peptides eluted from 10⁷ C1498 cells and 10⁵ DC were used for each mouse. Neither DC/CP vaccination (MST of 30 days) nor CP-peptide vaccination (MST of 28 days) was able to prolong the survival of mice compared to the nonvaccinated group (n = 11, MST 28 days). In contrast, mice receiving DC/TFA had a significantly improved survival compared with the control group of nonvaccinated mice (P < 0.0001). Results shown here are the cumulative results of two separate experiments